Shares of Revolution Medicines, Inc. (NASDAQ:RVMDW – Get Free Report) were down 10.5% during trading on Thursday . The company traded as low as $0.45 and last traded at $0.70. Approximately 241,800 shares traded hands during mid-day trading, an increase of 679% from the average daily volume of 31,057 shares. The stock had previously closed at $0.7821.
Revolution Medicines Stock Performance
The firm’s 50 day moving average is $0.56 and its two-hundred day moving average is $0.36.
About Revolution Medicines
Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.
Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.
Read More
- Five stocks we like better than Revolution Medicines
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- These 3 Banks Are Rallying Into Year-End, But Will It Continue?
- When to Sell a Stock for Profit or Loss
- 3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&P 500
- What is a Special Dividend?
- This ETF Caught a Major Tailwind After the Fed’s Rate Cut
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
